Immunotherapy Before and After Surgery Boosts Lung Cancer Outcomes
Pre- and post-surgical immunotherapy, combined with chemotherapy, improved survival rates for patients with operable non-small cell lung cancer in a phase 3 trial.
Category: Clinical Trials
Clinical Trials
Latest
Clinical Trials
Latest
Nucleoprotein-based Universal Flu Vaccine Candidate Shows Promise
A notable signal of protection of 84% was observed against symptomatic influenza infection in a phase 2a study.
Clinical Trials
Latest
Lung Support Supplement Improves Lung Function in Asthmatic Patients
A clinical trial of a probiotic and herbal supplement for lung health yielded promising results, including improvements in lung functions and quality of life scores in participants.
Janssen Ceases Development of RSV Vaccine for Adults
Janssen had been enrolling participants in a phase 3 trial to demonstrate the efficacy of its RSV vaccine candidate in adults age 60 and older.
Read More
Promising Anti-Tuberculosis Compound Headed to Trials
In preclinical mouse studies, CLB073 significantly enhanced the efficacy of Nix-TB drug regimen, the current standard of care for drug-resistant tuberculosis.
Read More
New Temperature-Stable Tuberculosis Vaccine Shows Promise in Phase 1 Trial
The trial evaluated the safety and immunogenicity of AAHI’s vaccine candidate compared to the previous iteration of the vaccine—a two-vial presentation that had demonstrated promising safety and immunogenicity in Phase 2 clinical testing.
Read More
aTyr Announces Phase 2 Study of SSc-ILD Drug
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read More
Merck’s Keytruda Meets Primary Endpoint in Phase 3 Trial for Lung Cancer
The US Food and Drug Administration has accepted Merck’s new supplemental Biologics License Application based on data from the trial.
Read More
Experimental Shionogi Antiviral Tested in Hospitalized COVID-19 Adults
A multisite clinical trial will evaluate an investigational COVID-19 antiviral known as the Shionogi antiviral (S-217622) or ensitrelvir fumaric acid.
Read More
Positive Data from Phase 1b/2a Study of Pulmonary Infection Treatment
BiomX has announced positive data from a study assessing the safety and tolerability of BX004 in nine cystic patients.
Read More
Vaxxas Starts Clinical Trial for Needle-Free, Seasonal Flu Patch
The trial will assess the safety, tolerability, and immunogenicity of the IIV4 candidate in approximately 150 healthy participants, aged 18 to 50.
Read More
Single-Dose RSV Shot for Infants Could Be Ready for Next Season
The target action date for the FDA’s approval decision is set for the third quarter. If approved, nirsevimab is expected to be available in the US for the 2023/2024 RSV season.
Read More
Moderna RSV Vaccine 83% Effective, Gets ‘Breakthrough’ Label from FDA
Phase 3 data found the Moderna RSV vaccine was 83.7% effective against RSV-associated lower respiratory tract disease in adults age 60 and older. The FDA has granted the vaccine a Breakthrough Therapy Designation.
Read More
FDA Panel to Convene to Review Promising RSV Vaccine Candidates
The FDA accepted Biologics License Applications and granted priority review for both Pfizer and GSK’s RSV older adult vaccine candidates last year following positive data from phase 3 trials.
Read More
COPD: Nebulized Ensifentrine Improved Lung Function, Reduced Exacerbations
A phase 3 clinical trial revealed that treatment with nebulized ensifentrine led to significant improvements in lung function, symptoms and quality of life measures in COPD patients.
Read More